A5089028589- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Cervical Cancer and HPV Research
- Phosphodiesterase function and regulation
- Cancer Immunotherapy and Biomarkers
- Cancer Research and Treatments
- Endometriosis Research and Treatment
- Uterine Myomas and Treatments
- DNA Repair Mechanisms
- Molecular Biology Techniques and Applications
- Global Cancer Incidence and Screening
- BRCA gene mutations in cancer
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- Bladder and Urothelial Cancer Treatments
- Angiogenesis and VEGF in Cancer
- Estrogen and related hormone effects
- Epigenetics and DNA Methylation
- Inflammatory mediators and NSAID effects
- Cancer Mechanisms and Therapy
- Ethics in Clinical Research
- Renal cell carcinoma treatment
- Colorectal and Anal Carcinomas
- Cancer-related molecular mechanisms research
USA Mitchell Cancer Institute
2016-2025
Emory University
2025
Piedmont Cancer Institute
2024
Winship Cancer Institute
2024
University of South Alabama
2014-2023
University of Virginia
2010-2017
Henry Ford Health System
2017
Indiana University – Purdue University Indianapolis
2017
University of North Carolina at Chapel Hill
2017
Las Vegas Institute
2017
Objective Aldehyde dehydrogenase (ALDH) expressing cells have been characterized as possessing stem cell-like properties. We evaluated ALDH+ ovarian cancer properties and their role in platinum resistance. Methods Isogenic cell lines for sensitivity (A2780) resistant (A2780/CP70) well ascites from patients were analyzed by flow cytometry to determine its association resistance, recurrence survival. A stable shRNA knockdown model ALDH1A1 was utilized effect on properties, cycle checkpoints,...
Background Immune checkpoint inhibitors are being considered for locally advanced cervical cancer (LACC) together with standard‐of‐care pelvic chemoradiation (CRT). However, the safety of combination and its optimal schedule unknown. Defining is a primary objective study examining concurrent sequential schedules. This article presents analysis that was fully accrued met reporting requirements. Methods Pembrolizumab given after CRT (arm 1) or during 2) according to randomized phase 2 design....
<div>AbstractPurpose:<p>Dual PD-1/CTLA-4 inhibition shows promise in various malignancies. The SWOG S1609 Dual Anti–CTLA-4 and Anti–PD-1 Blockade Rare Tumors (DART) trial presents initial results of ipilimumab/nivolumab vulvar cancers.</p>Patients Methods:<p>DART is a prospective/open-label/multicenter (1,016 US sites)/multicohort phase II clinical ipilimumab (1 mg/kg intravenously every 6 weeks) plus nivolumab (240 mg 2 weeks). primary endpoint was objective response...
The addition of immune checkpoint inhibitors to standard-of-care chemoradiation (CRT) is established as the new standard care in high-risk, locally advanced cervical cancer. However, optimal sequencing therapies unknown. Defining safety and feasibility combination was a primary objective this study examining concurrent versus sequential schedules. Pembrolizumab given after or during CRT randomized phase 2 design. Patients aged 18 years older with cancer, stages IB-IVA (according 2009...
Dihydronicotinamide rioside (NRH), the reduced form of nicotinamide riboside (NR), is a recently identified, naturally occurring precursor arguably most crucial cofactor for cellular function, adenine dinucleotide (NAD+). Recent investigation suggests that NRH more adept at increasing NAD+ stores than traditional precursors, and such extreme boosting via supplementation induces cytotoxicity in certain contexts. It has also been shown lack functional BRCA protein epithelial ovarian cancer...
// Kaushlendra Tripathi 1, * , Usama K. Hussein 2, Roja Anupalli 3, Reagan Barnett 1 Lavanya Bachaboina Jennifer Scalici Rodney P. Rocconi Laurie B. Owen Gary A. Piazza Komaraiah Palle Department of Oncologic Sciences, Mitchell Cancer Institute, University South Alabama, Mobile, USA 2 Faculty Science, Beni Suef University, Suef, Egypt 3 Genetics, Osmania Hyderabad, India These authors have contributed equally to this work Correspondence to: Palle, e-mail: kpalle@health.southalabama.edu...
(Abstracted from Lancet Oncol 2017;18:384–392) In more than 75% of women with endometrial cancer, the disease is confined to uterus. Recurrence risk defined by surgical staging lymphadenectomy and helps in decision give adjuvant treatment high-risk patients.
To describe the participation of minority women in clinical trials using immunologic agents for breast and gynecologic cancers.A retrospective review completed involving immunotherapy cancers was performed. Completed were examined data on race, tumor type, start year. Minority enrollment stratified by site. Based Center Disease Control Prevention age-adjusted incidence expected observed ratios racial calculated compared Χ2 testing, p≤0.05.A total 53 8820 patients reviewed. Breast cancer most...
BACKGROUND Mesothelium vascular cell adhesion molecule‐1 (VCAM‐1) expression in the metastatic epithelial ovarian cancer (EOC) microenvironment is induced by tumor and mediates invasion. VCAM‐1 imaging suggests during treatment an indicator of platinum resistance. Here, we assess potential prognostic significance mesothelium prospectively evaluate whether soluble (sVCAM‐1) a surrogate for expression. METHODS A retrospective review EOC patients was performed to outcomes with determined...
The inability to successfully treat women with ovarian cancer is due in large part the advanced stage of disease at diagnosis, development platinum resistance, and lack sensitive methods monitor tumor progression response treatment. Vascular cell adhesion molecule-1 (VCAM-1) expressed on mesothelium patients. We investigated VCAM-1 expression as a marker peritoneal metastasis platinum-based chemotherapy. <b>Methods:</b> Peritoneal or omental biopsies obtained from diagnosed I, II, III/IV...